Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)-Reference-Cited by-同舟云学术

Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

Published:2022-12-12 Issue:1 Volume:11 Page:83-96
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Alegre Adrián,Benzo Gonzalo,Alonso Rafael,Martínez-López Joaquín,Jimenez-Ubieto Ana,Cuéllar Clara,Askari Elham,Prieto Elena,Aláez Concepción,Aguado Beatriz,Velasco Alberto,Krsnik Isabel,Bocanegra Ana,Llorente Laura,Muñoz-Linares Cristina,Morales Ana,Giménez Eugenio,Iglesias Rebeca,Martínez-Chamorro Carmen,Alonso Aránzazu,Jiménez-Montes Carmen,Blanchard María J.,Alegre Adrián,Benzo Gonzalo,Alonso Rafael,Martínez-López Joaquín,Jimenez-Ubieto Ana,Cuéllar Clara,Askari Elham,Prieto Elena,Aláez Concepción,Aguado Beatriz,Velasco Alberto,Krsnik Isabel,Bocanegra Ana,Llorente Laura,Muñoz-Linares Cristina,Morales Ana,Giménez Eugenio,Iglesias Rebeca,Martínez-Chamorro Carmen,Alonso Aránzazu,Jiménez-Montes Carmen,Blanchard María J.,

Funder

GSK

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s40487-022-00212-5.pdf

Reference32 articles.

1. Sheikh S, Lebel E, Trudel S. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. Future Oncol. 2020;16(34):2783–98.

2. Joseph NS, Tai YT, Anderson KC, Lonial S. Novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor. Clin Pharmacol. 2021;13:169–80.

3. Becnel MR, Lee HC. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol. 2020;11:2040620720979813.

4. Demel I, Bago JR, Hajek R, Jelinek T. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. Br J Haematol. 2021;193(4):705–22.

5. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study;European Journal of Haematology;2024-05-09

2. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin;Oncotarget;2023-12-01

3. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02

4. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study;The Lancet Haematology;2023-10

5. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City;Cureus;2023-08-31